Verona Pharma plc
VRNA
Clasificación en acciones
#2228
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Precio por acción
$106.91
Última sincronización: 2025-10-07
Capitalización bursátil
$9.09B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
GB
Comercio Verona Pharma plc (VRNA)
Categoría
Healthcare
Ratio P/S de Verona Pharma plc (VRNA)
Ratio P/S al October 2026 TTM: 2.15K
Según los informes financieros más recientes y el precio de las acciones de Verona Pharma plc, el ratio P/S actual (TTM) es 2.15K. Al final de 2023, el ratio P/S era 0.00.
Historial del ratio P/S de Verona Pharma plc desde 2005 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 2.15K | 1,849.31% |
| 2024 | 110.41 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 3.77K | 37,827.00% |
| 2021 | 9.94 | 0.00% |
| 2020 | 0.00 | -100.00% |
| 2019 | 24.28K | -32.01% |
| 2018 | 35.71K | 65,523.71% |
| 2017 | 54.42 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | -99.53% |
US
|
|
| 40.55 | -98.12% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.53% |
NL
|
